Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMeclofenamic acid
Identification
- Name
- Meclofenamic acid
- Accession Number
- DB00939 (APRD01090)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]
- Structure
Structure for DB00939 (Meclofenamic acid)
- Synonyms
- Acide meclofenamique
- Acido meclofenamico
- Acidum meclofenamicum
- Meclofenamate
- N-(2,6-Dichloro-3-methylphenyl)anthranilic acid
- N-(2,6-Dichloro-m-tolyl)anthranilic acid
- N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid
- External IDs
- CI 583 / CI-583 / Cl 583 / INF 4668 / INF-4668
- Product Ingredients
Ingredient UNII CAS InChI Key Meclofenamate sodium 94NJ818U2W 67254-91-5 QHJLLDJTVQAFAN-UHFFFAOYSA-M - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Meclofenamate Sodium Capsule 50 mg/1 Oral Mylan Pharmaceuticals 1986-09-03 Not applicable US 
Meclofenamate Sodium Capsule 100 mg/1 Oral Mylan Pharmaceuticals 1986-09-03 Not applicable US - International/Other Brands
- Ethos (Yung Shin) / Eucome (U-Liang) / Meclomen (Pfizer)
- Categories
- Acids, Carbocyclic
- Amines
- Aminobenzoates
- Analgesics
- Analgesics, Non-Narcotic
- Aniline Compounds
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antiinflammatory Preparations, Non-Steroids for Topical Use
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- COX Inhibitors
- COX-1 Inhibitors
- COX-2 Inhibitors
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Fenamates
- Musculo-Skeletal System
- Nephrotoxic agents
- ortho-Aminobenzoates
- Peripheral Nervous System Agents
- Sensory System Agents
- Topical Products for Joint and Muscular Pain
- UNII
- 48I5LU4ZWD
- CAS number
- 644-62-2
- Weight
- Average: 296.149
Monoisotopic: 295.016684015 - Chemical Formula
- C14H11Cl2NO2
- InChI Key
- SBDNJUWAMKYJOX-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
- IUPAC Name
- 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
- SMILES
- CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
Pharmacology
- Indication
For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.
- Associated Conditions
- Pharmacodynamics
Meclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.
- Mechanism of action
The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.
Target Actions Organism AProstaglandin G/H synthase 1 inhibitorHuman AProstaglandin G/H synthase 2 inhibitorHuman AArachidonate 5-lipoxygenase inhibitorHuman UPotassium voltage-gated channel subfamily KQT member 2 otherHuman UPotassium voltage-gated channel subfamily KQT member 3 otherHuman - Absorption
Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (Cmax) decreased fourfold and the time to Cmax was delayed by 3 hours.
- Volume of distribution
- 9.1 to 43.2 L
- Protein binding
Greater than 99% bound to plasma proteins over a wide drug concentration range.
- Metabolism
Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.
- Route of elimination
Other metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.
- Half life
In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.
- Clearance
- Oral cl=206 mL/min
- Toxicity
After a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Meclofenamic acid. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 5-androstenedione. Experimental, Illicit Abciximab Meclofenamic acid may increase the anticoagulant activities of Abciximab. Approved Acebutolol Meclofenamic acid may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Meclofenamic acid may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Meclofenamic acid. Approved Alaproclate Alaproclate may increase the antiplatelet activities of Meclofenamic acid. Experimental Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Meclofenamic acid. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid. Approved Aliskiren Meclofenamic acid may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Meclofenamic acid. Experimental Alprenolol Meclofenamic acid may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Amcinonide. Approved Amikacin The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Amikacin. Approved, Investigational, Vet Approved Amiloride Meclofenamic acid may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aminosalicylic Acid. Approved Amlodipine The therapeutic efficacy of Amlodipine can be decreased when used in combination with Meclofenamic acid. Approved Ancrod Meclofenamic acid may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Meclofenamic acid. Investigational Androstenedione The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Meclofenamic acid. Investigational Antipyrine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine. Approved, Investigational Antithrombin III human Meclofenamic acid may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antrafenine. Approved Apixaban Meclofenamic acid may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Meclofenamic acid. Investigational Apramycin Meclofenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Meclofenamic acid. Approved, Investigational Arbekacin Meclofenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Meclofenamic acid may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Meclofenamic acid may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Meclofenamic acid may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Meclofenamic acid may decrease the antihypertensive activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Atamestane. Investigational Atenolol Meclofenamic acid may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Meclofenamic acid. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Meclofenamic acid. Approved Azficel-T The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Meclofenamic acid. Investigational Bacitracin The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Bacitracin. Approved, Vet Approved Balsalazide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Balsalazide. Approved, Investigational Bazedoxifene Meclofenamic acid may increase the thrombogenic activities of Bazedoxifene. Approved, Investigational Becaplermin Meclofenamic acid may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Meclofenamic acid. Approved, Investigational Befunolol Meclofenamic acid may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Meclofenamic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Meclofenamic acid. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Meclofenamic acid. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Meclofenamic acid. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Meclofenamic acid. Approved Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Meclofenamic acid. Approved Bepridil The therapeutic efficacy of Bepridil can be decreased when used in combination with Meclofenamic acid. Approved, Withdrawn Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Meclofenamic acid. Investigational Betamethasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betamethasone. Approved, Vet Approved Betaxolol Meclofenamic acid may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Meclofenamic acid. Approved, Investigational Bevantolol Meclofenamic acid may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Meclofenamic acid. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Bisoprolol Meclofenamic acid may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Meclofenamic acid may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Meclofenamic acid may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Meclofenamic acid. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Meclofenamic acid. Investigational Bucindolol Meclofenamic acid may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Meclofenamic acid. Approved Bufexamac The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bufexamac. Approved, Experimental Bufuralol Meclofenamic acid may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Meclofenamic acid. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Meclofenamic acid. Approved Bupranolol Meclofenamic acid may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Meclofenamic acid. Approved Candoxatril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Candoxatril. Experimental Capsaicin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Meclofenamic acid. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meclofenamic acid. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid. Approved, Vet Approved, Withdrawn Carteolol Meclofenamic acid may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Meclofenamic acid may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Meclofenamic acid. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Meclofenamic acid. Approved, Investigational Celiprolol Meclofenamic acid may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Meclofenamic acid may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Chlorotrianisene Meclofenamic acid may increase the thrombogenic activities of Chlorotrianisene. Investigational, Withdrawn Chlorphenesin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cilazapril. Approved Cimicoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cimicoxib. Investigational Cinoxacin Meclofenamic acid may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin Meclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cisplatin. Approved Citalopram Citalopram may increase the antiplatelet activities of Meclofenamic acid. Approved Clobetasol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Meclofenamic acid. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Meclofenamic acid. Vet Approved Cloranolol Meclofenamic acid may decrease the antihypertensive activities of Cloranolol. Experimental Clorindione Meclofenamic acid may increase the anticoagulant activities of Clorindione. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens Meclofenamic acid may increase the thrombogenic activities of Conjugated estrogens. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Meclofenamic acid. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meclofenamic acid. Experimental Cyclosporine The risk or severity of renal failure and hypertension can be increased when Meclofenamic acid is combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Meclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate. Approved Daidzein Meclofenamic acid may increase the thrombogenic activities of Daidzein. Experimental Dalteparin Meclofenamic acid may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Meclofenamic acid may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Dapoxetine Dapoxetine may increase the antiplatelet activities of Meclofenamic acid. Investigational Darexaban Meclofenamic acid may increase the anticoagulant activities of Darexaban. Investigational Deferasirox The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Delapril. Investigational Desipramine Meclofenamic acid may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Meclofenamic acid may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Desvenlafaxine Desvenlafaxine may increase the antiplatelet activities of Meclofenamic acid. Approved, Investigational Dexamethasone The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Meclofenamic acid. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meclofenamic acid. Approved, Investigational Dexniguldipine The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Meclofenamic acid. Experimental Dextran Meclofenamic acid may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin Meclofenamic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid. Approved, Vet Approved Dicoumarol Meclofenamic acid may increase the anticoagulant activities of Dicoumarol. Approved Dienestrol Meclofenamic acid may increase the thrombogenic activities of Dienestrol. Approved, Investigational Diethylstilbestrol Meclofenamic acid may increase the thrombogenic activities of Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Meclofenamic acid. Experimental Diflorasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid. Approved Dihydrostreptomycin Meclofenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Diltiazem The therapeutic efficacy of Diltiazem can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Meclofenamic acid. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meclofenamic acid. Approved Diphenadione Meclofenamic acid may increase the anticoagulant activities of Diphenadione. Experimental Doxazosin The therapeutic efficacy of Doxazosin can be decreased when used in combination with Meclofenamic acid. Approved Drospirenone Meclofenamic acid may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam. Withdrawn Duloxetine Duloxetine may increase the antiplatelet activities of Meclofenamic acid. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Meclofenamic acid. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Meclofenamic acid. Investigational Edetic Acid Meclofenamic acid may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Meclofenamic acid may increase the anticoagulant activities of Edoxaban. Approved Efonidipine The therapeutic efficacy of Efonidipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Enalapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalaprilat. Approved Enoxacin Meclofenamic acid may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Meclofenamic acid may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Meclofenamic acid. Experimental Epanolol Meclofenamic acid may decrease the antihypertensive activities of Epanolol. Experimental Epimestrol Meclofenamic acid may increase the thrombogenic activities of Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Meclofenamic acid. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Meclofenamic acid. Experimental Eplerenone Meclofenamic acid may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid. Approved Equilenin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilin. Approved Equol Meclofenamic acid may increase the thrombogenic activities of Equol. Investigational Esatenolol Meclofenamic acid may decrease the antihypertensive activities of Esatenolol. Experimental Escitalopram Escitalopram may increase the antiplatelet activities of Meclofenamic acid. Approved, Investigational Esmolol Meclofenamic acid may decrease the antihypertensive activities of Esmolol. Approved Estradiol acetate Meclofenamic acid may increase the thrombogenic activities of Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate Meclofenamic acid may increase the thrombogenic activities of Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate Meclofenamic acid may increase the thrombogenic activities of Estradiol valerate. Approved, Investigational, Vet Approved Estriol Meclofenamic acid may increase the thrombogenic activities of Estriol. Approved, Investigational, Vet Approved Estrogens, esterified Meclofenamic acid may increase the thrombogenic activities of Estrogens, esterified. Approved Estrone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Meclofenamic acid. Experimental Ethyl biscoumacetate Meclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Meclofenamic acid. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Meclofenamic acid. Approved, Investigational Etoperidone Etoperidone may increase the antiplatelet activities of Meclofenamic acid. Withdrawn Etoricoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Meclofenamic acid. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Meclofenamic acid. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Meclofenamic acid. Experimental Felodipine The therapeutic efficacy of Felodipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Meclofenamic acid. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Meclofenamic acid. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Meclofenamic acid. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Meclofenamic acid. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Meclofenamic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Meclofenamic acid. Approved, Investigational Fleroxacin Meclofenamic acid may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Meclofenamic acid. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fludrocortisone. Approved, Investigational Fluindione Meclofenamic acid may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Meclofenamic acid may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Meclofenamic acid. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Meclofenamic acid. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluorometholone. Approved, Investigational Fluoxetine Fluoxetine may increase the antiplatelet activities of Meclofenamic acid. Approved, Vet Approved Fluprednidene The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Meclofenamic acid. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Meclofenamic acid. Approved Fluvoxamine Fluvoxamine may increase the antiplatelet activities of Meclofenamic acid. Approved, Investigational Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Meclofenamic acid. Approved, Nutraceutical, Vet Approved Fondaparinux Meclofenamic acid may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid. Experimental Formestane The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Fosinopril. Approved Framycetin Meclofenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Gabexate Meclofenamic acid may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Meclofenamic acid may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Meclofenamic acid may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Meclofenamic acid. Approved, Withdrawn Gemifloxacin Meclofenamic acid may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Meclofenamic acid may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Genistein Meclofenamic acid may increase the thrombogenic activities of Genistein. Investigational Gentamicin Meclofenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Meclofenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ginseng. Approved, Investigational, Nutraceutical Glipizide The protein binding of Glipizide can be decreased when combined with Meclofenamic acid. Approved, Investigational Glyburide The protein binding of Glyburide can be decreased when combined with Meclofenamic acid. Approved Grepafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Meclofenamic acid. Experimental Guanfacine The therapeutic efficacy of Guanfacine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Halcinonide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HE3286. Investigational Heparin Meclofenamic acid may increase the anticoagulant activities of Heparin. Approved, Investigational Hexestrol Meclofenamic acid may increase the thrombogenic activities of Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Meclofenamic acid. Investigational Hydralazine Meclofenamic acid may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Hydrocortisone The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Meclofenamic acid. Approved, Vet Approved Hydrocortisone acetate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Meclofenamic acid. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Meclofenamic acid. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Hygromycin B Meclofenamic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Meclofenamic acid. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Meclofenamic acid. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icosapent. Approved, Nutraceutical Idraparinux Meclofenamic acid may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Meclofenamic acid. Experimental Indalpine Indalpine may increase the antiplatelet activities of Meclofenamic acid. Investigational, Withdrawn Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid. Approved Indenolol Meclofenamic acid may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Meclofenamic acid. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Meclofenamic acid. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid. Approved, Investigational Isepamicin Meclofenamic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Meclofenamic acid. Withdrawn Isradipine The therapeutic efficacy of Isradipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Istaroxime. Investigational Kanamycin Meclofenamic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Meclofenamic acid. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid. Approved Labetalol Meclofenamic acid may decrease the antihypertensive activities of Labetalol. Approved Lacidipine The therapeutic efficacy of Lacidipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Landiolol Meclofenamic acid may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Meclofenamic acid. Approved, Investigational Lepirudin Meclofenamic acid may increase the anticoagulant activities of Lepirudin. Approved Lercanidipine The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Letaxaban Meclofenamic acid may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol Meclofenamic acid may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Meclofenamic acid may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Meclofenamic acid may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Levomilnacipran Levomilnacipran may increase the antiplatelet activities of Meclofenamic acid. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Meclofenamic acid. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Meclofenamic acid. Experimental Lomefloxacin Meclofenamic acid may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Meclofenamic acid. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Meclofenamic acid. Approved Loteprednol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Meclofenamic acid. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Meclofenamic acid. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate. Approved Manidipine The therapeutic efficacy of Manidipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with ME-609. Investigational Medrysone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid. Approved Melagatran Meclofenamic acid may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid. Approved, Vet Approved Mepindolol Meclofenamic acid may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Meclofenamic acid. Approved Mestranol Meclofenamic acid may increase the thrombogenic activities of Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Meclofenamic acid. Approved, Investigational, Withdrawn Methallenestril Meclofenamic acid may increase the thrombogenic activities of Methallenestril. Experimental Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid. Approved Methyl salicylate The therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Methylprednisolone The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Meclofenamic acid. Approved, Vet Approved Metipranolol Meclofenamic acid may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid. Approved Metoprolol Meclofenamic acid may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Mibefradil The therapeutic efficacy of Mibefradil can be decreased when used in combination with Meclofenamic acid. Investigational, Withdrawn Micronomicin Meclofenamic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Meclofenamic acid. Approved, Experimental Milnacipran Milnacipran may increase the antiplatelet activities of Meclofenamic acid. Approved, Investigational Minoxidil The therapeutic efficacy of Minoxidil can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Meclofenamic acid. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Meclofenamic acid. Investigational Moexipril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Meclofenamic acid. Experimental Mometasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Meclofenamic acid. Approved Moxestrol Meclofenamic acid may increase the thrombogenic activities of Moxestrol. Experimental Moxifloxacin Meclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Meclofenamic acid. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Meclofenamic acid. Approved Nadolol Meclofenamic acid may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Meclofenamic acid may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Meclofenamic acid. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Meclofenamic acid. Approved Naftopidil The therapeutic efficacy of Naftopidil can be decreased when used in combination with Meclofenamic acid. Investigational Nalidixic Acid Meclofenamic acid may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 1022. Investigational Neamine Meclofenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Meclofenamic acid may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nefazodone Nefazodone may increase the antiplatelet activities of Meclofenamic acid. Approved, Withdrawn Nemonoxacin Meclofenamic acid may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Neomycin. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Meclofenamic acid. Approved, Investigational Netilmicin Meclofenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Meclofenamic acid. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid. Approved Niguldipine The therapeutic efficacy of Niguldipine can be decreased when used in combination with Meclofenamic acid. Experimental Nilvadipine The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The therapeutic efficacy of Nimodipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Nisoldipine The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Meclofenamic acid. Approved Nitrendipine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Meclofenamic acid. Investigational Norfloxacin Meclofenamic acid may increase the neuroexcitatory activities of Norfloxacin. Approved Ofloxacin Meclofenamic acid may increase the neuroexcitatory activities of Ofloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Meclofenamic acid. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Meclofenamic acid. Vet Approved Otamixaban Meclofenamic acid may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin. Approved Oxolinic acid Meclofenamic acid may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Meclofenamic acid may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Meclofenamic acid. Approved, Withdrawn Palmidrol The risk or severity of adverse effects can be increased when Palmidrol is combined with Meclofenamic acid. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parecoxib. Approved Paromomycin The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Paromomycin. Approved, Investigational Paroxetine Paroxetine may increase the antiplatelet activities of Meclofenamic acid. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Meclofenamic acid. Approved, Investigational Pazufloxacin Meclofenamic acid may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Meclofenamic acid may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Meclofenamic acid may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Meclofenamic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Meclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Perindopril. Approved Phenindione Meclofenamic acid may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Meclofenamic acid may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid. Approved, Investigational Pindolol Meclofenamic acid may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Meclofenamic acid may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Meclofenamic acid. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Meclofenamic acid. Approved, Investigational Piromidic acid Meclofenamic acid may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Meclofenamic acid. Experimental Pitolisant The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Meclofenamic acid may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Meclofenamic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polyestradiol phosphate Meclofenamic acid may increase the thrombogenic activities of Polyestradiol phosphate. Approved Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Meclofenamic acid. Approved Pomalidomide The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pomalidomide. Approved Potassium Citrate Meclofenamic acid may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Meclofenamic acid may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Meclofenamic acid. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Meclofenamic acid. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Meclofenamic acid. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Meclofenamic acid. Experimental Promestriene Meclofenamic acid may increase the thrombogenic activities of Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Meclofenamic acid. Approved, Investigational Propafenone Meclofenamic acid may decrease the antihypertensive activities of Propafenone. Approved Propranolol Meclofenamic acid may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Meclofenamic acid. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Meclofenamic acid. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Meclofenamic acid. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Meclofenamic acid. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Meclofenamic acid. Vet Approved Protein C Meclofenamic acid may increase the anticoagulant activities of Protein C. Approved Protein S human Meclofenamic acid may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Meclofenamic acid may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Meclofenamic acid may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Meclofenamic acid. Investigational Puromycin Meclofenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Quinapril. Approved, Investigational Quinestrol Meclofenamic acid may increase the thrombogenic activities of Quinestrol. Approved Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid. Approved Ramipril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol. Approved, Experimental, Investigational Reviparin Meclofenamic acid may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Meclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate. Approved, Investigational Rivaroxaban Meclofenamic acid may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Meclofenamic acid. Approved, Investigational, Withdrawn Rosoxacin Meclofenamic acid may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Meclofenamic acid may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Meclofenamic acid. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Meclofenamic acid. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Meclofenamic acid. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Meclofenamic acid. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Meclofenamic acid. Approved, Investigational Secoisolariciresinol Meclofenamic acid may increase the thrombogenic activities of Secoisolariciresinol. Investigational Seliciclib The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Meclofenamic acid. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Meclofenamic acid. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Meclofenamic acid. Investigational Sertraline Sertraline may increase the antiplatelet activities of Meclofenamic acid. Approved Sisomicin Meclofenamic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium Citrate The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Sodium Citrate. Approved, Investigational Sodium phosphate, monobasic The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Meclofenamic acid. Approved Sotalol Meclofenamic acid may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin Meclofenamic acid may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Spirapril. Approved Spironolactone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Meclofenamic acid. Investigational Streptomycin Meclofenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meclofenamic acid. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid. Approved, Investigational Sulodexide Meclofenamic acid may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Meclofenamic acid. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Meclofenamic acid. Experimental Synthetic Conjugated Estrogens, A Meclofenamic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B Meclofenamic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B. Approved Tacrolimus Meclofenamic acid may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Meclofenamic acid. Approved Talinolol Meclofenamic acid may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Meclofenamic acid. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Meclofenamic acid. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Meclofenamic acid. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid. Approved, Investigational Temafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Meclofenamic acid. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Meclofenamic acid. Vet Approved Terbutaline Meclofenamic acid may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Meclofenamic acid. Approved Tertatolol Meclofenamic acid may decrease the antihypertensive activities of Tertatolol. Experimental Tetrahydropalmatine The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Meclofenamic acid. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid. Approved Tibolone Meclofenamic acid may increase the thrombogenic activities of Tibolone. Approved, Investigational Tiludronic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Meclofenamic acid may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Meclofenamic acid. Investigational Tioclomarol Meclofenamic acid may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tixocortol. Approved, Withdrawn Tobramycin Meclofenamic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Meclofenamic acid. Approved Trandolapril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trandolapril. Approved Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triamcinolone. Approved, Vet Approved Triamterene Meclofenamic acid may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Meclofenamic acid. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Meclofenamic acid. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trolamine salicylate. Approved Trovafloxacin Meclofenamic acid may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Meclofenamic acid may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Meclofenamic acid. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Meclofenamic acid. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid. Approved, Investigational Vancomycin Meclofenamic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level. Approved Venlafaxine Venlafaxine may increase the antiplatelet activities of Meclofenamic acid. Approved Warfarin Meclofenamic acid may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Meclofenamic acid may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Meclofenamic acid. Approved, Investigational Zeranol Meclofenamic acid may increase the thrombogenic activities of Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Meclofenamic acid. Approved, Investigational, Withdrawn Zimelidine Zimelidine may increase the antiplatelet activities of Meclofenamic acid. Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Meclofenamic acid. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
U.S. Patent 3,313,848.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015074
- KEGG Drug
- D02341
- KEGG Compound
- C07117
- PubChem Compound
- 4037
- PubChem Substance
- 46507887
- ChemSpider
- 3897
- BindingDB
- 22971
- ChEBI
- 6710
- ChEMBL
- CHEMBL509
- Therapeutic Targets Database
- DNC000919
- PharmGKB
- PA450341
- HET
- JMS
- RxList
- RxList Drug Page
- Wikipedia
- Meclofenamic_acid
- ATC Codes
- M01AG04 — Meclofenamic acid
- M01AG — Fenamates
- M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
- M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
- M — MUSCULO-SKELETAL SYSTEM
- PDB Entries
- 3r6i / 4n6p / 4qkn / 5ikq
- MSDS
- Download (74.2 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Enrolling by Invitation Treatment Bipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders 1 Not Available Active Not Recruiting Treatment Progressive Brain Metastases / Recurrent Brain Metastases 1
Pharmacoeconomics
- Manufacturers
- Quantum pharmics ltd
- American therapeutics inc
- Barr laboratories inc
- Mylan pharmaceuticals inc
- Par pharmaceutical inc
- Sandoz inc
- Usl pharma inc
- Vitarine pharmaceuticals inc
- Watson laboratories inc
- Parke davis div warner lambert co
- Packagers
- Dispensing Solutions
- Mylan
- Nucare Pharmaceuticals Inc.
- Pharmedix
- Physicians Total Care Inc.
- Sandhills Packaging Inc.
- Dosage forms
Form Route Strength Capsule Oral 100 mg/1 Capsule Oral 50 mg/1 - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 248-250 U.S. Patent 3,313,848. water solubility 30 mg/L MERCK INDEX (1996) logP 5 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00366 mg/mL ALOGPS logP 5.11 ALOGPS logP 6.09 ChemAxon logS -4.9 ALOGPS pKa (Strongest Acidic) 3.79 ChemAxon pKa (Strongest Basic) -3.6 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 49.33 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 76.45 m3·mol-1 ChemAxon Polarizability 28.44 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9393 Blood Brain Barrier + 0.8668 Caco-2 permeable + 0.8398 P-glycoprotein substrate Non-substrate 0.806 P-glycoprotein inhibitor I Non-inhibitor 0.8943 P-glycoprotein inhibitor II Non-inhibitor 0.9474 Renal organic cation transporter Non-inhibitor 0.9094 CYP450 2C9 substrate Non-substrate 0.6402 CYP450 2D6 substrate Non-substrate 0.9164 CYP450 3A4 substrate Non-substrate 0.6566 CYP450 1A2 substrate Inhibitor 0.9236 CYP450 2C9 inhibitor Inhibitor 0.9106 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.8271 CYP450 3A4 inhibitor Non-inhibitor 0.8308 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.558 Ames test Non AMES toxic 0.8633 Carcinogenicity Non-carcinogens 0.5329 Biodegradation Not ready biodegradable 0.9709 Rat acute toxicity 3.0345 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9502 hERG inhibition (predictor II) Non-inhibitor 0.872
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Aminobenzoic acids
- Alternative Parents
- Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Dichlorobenzenes / Benzoyl derivatives / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives show 6 more
- Substituents
- Aminobenzoic acid / Benzoic acid / Benzoyl / 1,3-dichlorobenzene / Aniline or substituted anilines / Aminotoluene / Toluene / Chlorobenzene / Halobenzene / Aryl chloride show 19 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:6710)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. [PubMed:12225961]
- Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83. [PubMed:11094641]
- Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
- Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
- Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4. [PubMed:8454631]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
- Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45. [PubMed:12409963]
- Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
- Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14. [PubMed:16290292]
- Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. [PubMed:7825862]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Iron ion binding
- Specific Function
- Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
- Gene Name
- ALOX5
- Uniprot ID
- P09917
- Uniprot Name
- Arachidonate 5-lipoxygenase
- Molecular Weight
- 77982.595 Da
References
- Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34. [PubMed:1539679]
- Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38. [PubMed:3020588]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current...
- Gene Name
- KCNQ2
- Uniprot ID
- O43526
- Uniprot Name
- Potassium voltage-gated channel subfamily KQT member 2
- Molecular Weight
- 95846.575 Da
References
- Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native ...
- Gene Name
- KCNQ3
- Uniprot ID
- O43525
- Uniprot Name
- Potassium voltage-gated channel subfamily KQT member 3
- Molecular Weight
- 96741.515 Da
References
- Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Thyroid hormone transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-gluc...
- Gene Name
- SLCO1C1
- Uniprot ID
- Q9NYB5
- Uniprot Name
- Solute carrier organic anion transporter family member 1C1
- Molecular Weight
- 78695.625 Da
References
- Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:51